Coverage Snapshot: Medical weight-loss and GLP-1 clinics should review professional liability, product and compounding-related liability, cyber/HIPAA exposure, and general liability together, especially if the practice uses telehealth or compounded medication. The right review depends on the prescribing model, medication sourcing, screening protocols, and whether care is delivered in person, by telehealth, or both.
Why sourcing became a bigger question in 2025-2026
Compounded semaglutide and tirzepatide were widely available while the FDA listed both drugs as being in shortage. Once the agency lifted the shortage designations (tirzepatide in December 2024, semaglutide in February 2025), the regulatory basis for broad compounding narrowed, and clinics that kept sourcing compounded product from the same channels took on a different regulatory posture than they had during the shortage period.
What underwriters tend to ask about sourcing
Expect questions about whether medication is sourced from a licensed 503A or 503B compounding pharmacy, whether the clinic has documentation supporting medical necessity for any compounded product, and how prescribing decisions are documented for telehealth patients versus in-person visits. Clinics that cannot answer these clearly may see it reflected in underwriting.
Where this intersects with malpractice exposure
Sourcing questions do not stay contained to product liability. If a patient has an adverse reaction, the clinic’s ability to show where the medication came from, how dosing was decided, and how the patient was screened and monitored often becomes part of the malpractice defense, not just a regulatory question.
Common questions
Does a medspa policy automatically include GLP-1 prescribing?
Not automatically. Coverage depends on how the policy defines covered services, and whether the carrier has been told the practice added GLP-1 or weight-management services.
Does medication sourcing matter for insurance purposes?
It can. Compounded-medication sourcing has become a more active regulatory and underwriting topic since 2025 FDA compounding guidance changed, so documentation of sourcing is worth having ready.
For a full breakdown of the exposures WHINS reviews on this niche, and to start an intake, see the GLP-1 & Weight-Loss Clinic Insurance page.
Written by Karen Fatta, Insurance Advisor at WHINS Insurance Agency. CA License #0K54183 | NPN #17751191.
This post is for educational and marketing purposes only and does not constitute legal, tax, medical, regulatory, underwriting, or coverage advice. Coverage is subject to underwriting, carrier appetite, applicable law, and the terms, conditions, limitations, and exclusions of the issued policy.
